Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8721929 | Digestive and Liver Disease | 2018 | 12 Pages |
Abstract
The primary endpoint of the study is 3-year disease-free survival (DFS). Hypotheses are to improve 3-years DFS from placebo: 72% to aspirin: 83% (HRâ¯=â¯0.56). 94 events and 264 patients with PIK3CA mutation are required. The secondary endpoints are DFS at 5 years, the overall survival rate at 5 years, grade 3-4 severe bleeding.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Pierre Michel, Valerie Boige, Thierry Andre, Thomas Aparicio, Jean Baptiste Bachet, Laetitia Dahan, Rosine Guimbaud, Côme Lepage, Sylvain Manfredi, David Tougeron, Julien Taieb, Janick Selves, Karine Le Malicot, Frederic Di Fiore, Emilie Maillard,